Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-7drxs Total loading time: 0 Render date: 2024-07-17T08:21:55.980Z Has data issue: false hasContentIssue false

Chapter 49 - Hematopoietic Cell Transplantation for Immunoglobulin Light Chain (AL) Amyloidosis

from Section 13 - Plasma Cell Dyscrasias: Hematopoietic Cell Transplants

Published online by Cambridge University Press:  24 May 2017

By
Taimur Sher  and
Morie A. Gertz
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 477 - 484
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kyle, RA, Gertz, MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 32(1), 45–59 (1995).Google ScholarPubMed
Palladini, G, Perfetti, V, Obici, L et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103(8), 2936–2938 (2004).CrossRefGoogle ScholarPubMed
Gertz, MA, Kyle, RA. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Archiv Intern Med, 150(3), 629–633 (1990).CrossRefGoogle ScholarPubMed
Comenzo, RL, Vosburgh, E, Simms, RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood, 88(7), 2801–2806 (1996).CrossRefGoogle ScholarPubMed
Comenzo, RL, Vosburgh, E, Falk, RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91(10), 3662–3670 (1998).CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med, 113(7), 549–555 (2002).CrossRefGoogle ScholarPubMed
Moreau, P, Leblond, V, Bourquelot, P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol, 101(4), 766–769 (1998).CrossRefGoogle ScholarPubMed
Jaccard, A, Moreau, P, Leblond, V et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New Engl J Med, 357(11), 1083–1093 (2007).CrossRefGoogle ScholarPubMed
Migrino, RQ, Mareedu, RK, Eastwood, D, Bowers, M, Harmann, L, Hari, P. Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr, 22(12), 1396–1402 (2009).CrossRefGoogle ScholarPubMed
Comenzo, RL, Gertz, MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99(12), 4276–4282 (2002).CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant, 46(7), 970–975 (2011).CrossRefGoogle ScholarPubMed
Tsai, SB, Seldin, DC, Quillen, K et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood, 120(22), 4445–4446 (2012).CrossRefGoogle Scholar
Dispenzieri, A, Gertz, MA, Kyle, RA et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol, 22(18), 3751–3757 (2004).CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma, 51(12), 2181–2187 (2010).CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica, 92(10), 1415–1418 (2007).CrossRefGoogle ScholarPubMed
Girnius, S, Seldin, DC, Skinner, M et al. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Ann Hematol, 89(6), 579–584 (2010).CrossRefGoogle Scholar
Dispenzieri, A, Lacy, MQ, Katzmann, JA et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107(8), 3378–3383 (2006).CrossRefGoogle ScholarPubMed
Kumar, S, Dispenzieri, A, Lacy, MQ et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol, 30(9), 989–995 (2012).CrossRefGoogle ScholarPubMed
Johnston, PB, Lacy, MQ, Dispenzieri, A, et al. Toxicities associated with stem cell mobilization utilizing cyclophosphamide and grown factor versus G-CSF alone in primary systemic amyloidosis [abstract]. Blood, 96, 182a (2000).Google Scholar
Leung, N, Leung, TR, Cha, SS, Dispenzieri, A, Lacy, MQ, Gertz, MA. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood, 106(10), 3353–3357 (2005).CrossRefGoogle ScholarPubMed
Kumar, S, Dispenzieri, A, Lacy, MQ, Litzow, MR, Gertz, MA. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant, 28(4), 381–385 (2001).CrossRefGoogle ScholarPubMed
Hoshino, Y, Hatake, K, Muroi, K et al. Bleeding tendency caused by the deposit of amyloid substance in the perivascular region. Intern Med, 32(11), 879–881 (1993).CrossRefGoogle ScholarPubMed
Choufani, EB, Sanchorawala, V, Ernst, T et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood, 97(6), 1885–1887 (2001).CrossRefGoogle ScholarPubMed
Falk, RH, Rubinow, A, Cohen, AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am College Cardiol, 3(1), 107–113 (1984).CrossRefGoogle ScholarPubMed
Dispenzieri, A, Kyle, RA, Lacy, MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood, 103(10), 3960–3963 (2004).CrossRefGoogle ScholarPubMed
Kumar, S, Gertz, M, Lacy, M et al. Recent improvements in survival in light chain amyloidosis and the importance of an early mortality risk score. Blood, 19, 116–121 (2010).Google Scholar
Dubrey, SW, Burke, MM, Hawkins, PN, Banner, NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant, 23(10), 1142–1153 (2004).CrossRefGoogle ScholarPubMed
Gillmore, JD, Goodman, HJ, Lachmann, HJ et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107(3), 1227–1229 (2006).CrossRefGoogle ScholarPubMed
Mikhael, JR, Schuster, SR, Jimenez-Zepeda, VH et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 119(19), 4391–4394 (2012).CrossRefGoogle ScholarPubMed
Sanchorawala, V, Quillen, K, Sloan, JM, Andrea, NT, Seldin, DC. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica, 96(12), 1890–1892 (2011).CrossRefGoogle ScholarPubMed
Landau, H, Hassoun, H, Bello, C et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid, 18 Suppl 1, 130–131 (2011).CrossRefGoogle ScholarPubMed
Warsame, R, Bang, SM, Kumar, SK et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. Eur J Haematol, 92(6), 485–490 (2014).CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×